Advancing treatment for metastatic bone cancer: Consensus recommendations from the second cambridge conference

Robert E. Coleman, Theresa Guise, Allan Lipton, G. David Roodman, James R. Berenson, Jean Jacques Body, Brendan F. Boyce, Laura M. Calvi, Peyman Hadji, Eugene V. McCloskey, Fred Saad, Matthew R. Smith, Larry J. Suva, Russell S. Taichman, Robert L. Vessella, Katherine N. Weilbaecher

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Purpose: Summarize current knowledge, critical gaps in knowledge, and recommendations to advance the field of metastatic bone cancer. Experimental Design: A multidisciplinary consensus conference was convened to review recent progress in basic and clinical research, assess critical gaps in current knowledge, and prioritize recommendations to advance research in the next 5 years. The program addressed three principal topics: biology of metastasis, preserving normal bone health, and optimizing bone-targeted therapies. Results: A variety of specific recommendations were identified as important to advance research and clinical care over the next 5 years. Conclusions: Priorities for research in bone biology include characterizing components of the stem cell niche in bone, developing oncogenic immunocompetent animal models of bone metastasis, and investigating the unique contribution of the bone microenvironment to tumor growth and dormancy. Priorities for research in preserving normal bone health include developing methods to measure and characterize disseminating tumor cells, assessing outcomes from the major prevention trials currently in progress, and improving methodologies to assess risks and benefits of treatment. Priorities for optimizing bone-targeted therapies include advancing studies of serum proteomics and genomics to reliably identify patients who will develop bone metastases, enhancing imaging for early detection of bone metastases and early response evaluation, and developing new tests to evaluate response to bone-directed treatments.

Original languageEnglish (US)
Pages (from-to)6387-6395
Number of pages9
JournalClinical Cancer Research
Volume14
Issue number20
DOIs
StatePublished - Oct 15 2008
Externally publishedYes

Fingerprint

Bone Neoplasms
Bone and Bones
Therapeutics
Neoplasm Metastasis
Research
Stem Cell Niche
Tumor Microenvironment
Health
Genomics
Proteomics
Research Design
Animal Models

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Advancing treatment for metastatic bone cancer : Consensus recommendations from the second cambridge conference. / Coleman, Robert E.; Guise, Theresa; Lipton, Allan; Roodman, G. David; Berenson, James R.; Body, Jean Jacques; Boyce, Brendan F.; Calvi, Laura M.; Hadji, Peyman; McCloskey, Eugene V.; Saad, Fred; Smith, Matthew R.; Suva, Larry J.; Taichman, Russell S.; Vessella, Robert L.; Weilbaecher, Katherine N.

In: Clinical Cancer Research, Vol. 14, No. 20, 15.10.2008, p. 6387-6395.

Research output: Contribution to journalArticle

Coleman, RE, Guise, T, Lipton, A, Roodman, GD, Berenson, JR, Body, JJ, Boyce, BF, Calvi, LM, Hadji, P, McCloskey, EV, Saad, F, Smith, MR, Suva, LJ, Taichman, RS, Vessella, RL & Weilbaecher, KN 2008, 'Advancing treatment for metastatic bone cancer: Consensus recommendations from the second cambridge conference', Clinical Cancer Research, vol. 14, no. 20, pp. 6387-6395. https://doi.org/10.1158/1078-0432.CCR-08-1572
Coleman, Robert E. ; Guise, Theresa ; Lipton, Allan ; Roodman, G. David ; Berenson, James R. ; Body, Jean Jacques ; Boyce, Brendan F. ; Calvi, Laura M. ; Hadji, Peyman ; McCloskey, Eugene V. ; Saad, Fred ; Smith, Matthew R. ; Suva, Larry J. ; Taichman, Russell S. ; Vessella, Robert L. ; Weilbaecher, Katherine N. / Advancing treatment for metastatic bone cancer : Consensus recommendations from the second cambridge conference. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 20. pp. 6387-6395.
@article{5b0100358c3b4b8a9278b826efffe5c8,
title = "Advancing treatment for metastatic bone cancer: Consensus recommendations from the second cambridge conference",
abstract = "Purpose: Summarize current knowledge, critical gaps in knowledge, and recommendations to advance the field of metastatic bone cancer. Experimental Design: A multidisciplinary consensus conference was convened to review recent progress in basic and clinical research, assess critical gaps in current knowledge, and prioritize recommendations to advance research in the next 5 years. The program addressed three principal topics: biology of metastasis, preserving normal bone health, and optimizing bone-targeted therapies. Results: A variety of specific recommendations were identified as important to advance research and clinical care over the next 5 years. Conclusions: Priorities for research in bone biology include characterizing components of the stem cell niche in bone, developing oncogenic immunocompetent animal models of bone metastasis, and investigating the unique contribution of the bone microenvironment to tumor growth and dormancy. Priorities for research in preserving normal bone health include developing methods to measure and characterize disseminating tumor cells, assessing outcomes from the major prevention trials currently in progress, and improving methodologies to assess risks and benefits of treatment. Priorities for optimizing bone-targeted therapies include advancing studies of serum proteomics and genomics to reliably identify patients who will develop bone metastases, enhancing imaging for early detection of bone metastases and early response evaluation, and developing new tests to evaluate response to bone-directed treatments.",
author = "Coleman, {Robert E.} and Theresa Guise and Allan Lipton and Roodman, {G. David} and Berenson, {James R.} and Body, {Jean Jacques} and Boyce, {Brendan F.} and Calvi, {Laura M.} and Peyman Hadji and McCloskey, {Eugene V.} and Fred Saad and Smith, {Matthew R.} and Suva, {Larry J.} and Taichman, {Russell S.} and Vessella, {Robert L.} and Weilbaecher, {Katherine N.}",
year = "2008",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-08-1572",
language = "English (US)",
volume = "14",
pages = "6387--6395",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Advancing treatment for metastatic bone cancer

T2 - Consensus recommendations from the second cambridge conference

AU - Coleman, Robert E.

AU - Guise, Theresa

AU - Lipton, Allan

AU - Roodman, G. David

AU - Berenson, James R.

AU - Body, Jean Jacques

AU - Boyce, Brendan F.

AU - Calvi, Laura M.

AU - Hadji, Peyman

AU - McCloskey, Eugene V.

AU - Saad, Fred

AU - Smith, Matthew R.

AU - Suva, Larry J.

AU - Taichman, Russell S.

AU - Vessella, Robert L.

AU - Weilbaecher, Katherine N.

PY - 2008/10/15

Y1 - 2008/10/15

N2 - Purpose: Summarize current knowledge, critical gaps in knowledge, and recommendations to advance the field of metastatic bone cancer. Experimental Design: A multidisciplinary consensus conference was convened to review recent progress in basic and clinical research, assess critical gaps in current knowledge, and prioritize recommendations to advance research in the next 5 years. The program addressed three principal topics: biology of metastasis, preserving normal bone health, and optimizing bone-targeted therapies. Results: A variety of specific recommendations were identified as important to advance research and clinical care over the next 5 years. Conclusions: Priorities for research in bone biology include characterizing components of the stem cell niche in bone, developing oncogenic immunocompetent animal models of bone metastasis, and investigating the unique contribution of the bone microenvironment to tumor growth and dormancy. Priorities for research in preserving normal bone health include developing methods to measure and characterize disseminating tumor cells, assessing outcomes from the major prevention trials currently in progress, and improving methodologies to assess risks and benefits of treatment. Priorities for optimizing bone-targeted therapies include advancing studies of serum proteomics and genomics to reliably identify patients who will develop bone metastases, enhancing imaging for early detection of bone metastases and early response evaluation, and developing new tests to evaluate response to bone-directed treatments.

AB - Purpose: Summarize current knowledge, critical gaps in knowledge, and recommendations to advance the field of metastatic bone cancer. Experimental Design: A multidisciplinary consensus conference was convened to review recent progress in basic and clinical research, assess critical gaps in current knowledge, and prioritize recommendations to advance research in the next 5 years. The program addressed three principal topics: biology of metastasis, preserving normal bone health, and optimizing bone-targeted therapies. Results: A variety of specific recommendations were identified as important to advance research and clinical care over the next 5 years. Conclusions: Priorities for research in bone biology include characterizing components of the stem cell niche in bone, developing oncogenic immunocompetent animal models of bone metastasis, and investigating the unique contribution of the bone microenvironment to tumor growth and dormancy. Priorities for research in preserving normal bone health include developing methods to measure and characterize disseminating tumor cells, assessing outcomes from the major prevention trials currently in progress, and improving methodologies to assess risks and benefits of treatment. Priorities for optimizing bone-targeted therapies include advancing studies of serum proteomics and genomics to reliably identify patients who will develop bone metastases, enhancing imaging for early detection of bone metastases and early response evaluation, and developing new tests to evaluate response to bone-directed treatments.

UR - http://www.scopus.com/inward/record.url?scp=58149179539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149179539&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1572

DO - 10.1158/1078-0432.CCR-08-1572

M3 - Article

C2 - 18927277

AN - SCOPUS:58149179539

VL - 14

SP - 6387

EP - 6395

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -